Lindbrook Capital, LLC Fibrogen Inc Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$2.49 - $20.59 $1,329 - $10,995	-534 Reduced 93.19%	39 $0
Q1 2023 Apr 26, 2023	SELL	$15.95 - $25.18 $2,408 - $3,802	-151 Reduced 20.86%	573 $10,000
Q4 2022 Jan 24, 2023	BUY	$13.27 - $17.73 $6,834 - $9,130	515 Added 246.41%	724 $0
Q3 2022 Nov 10, 2022	BUY	$11.4 - $14.6 $444 - $569	39 Added 22.94%	209 $3,000
Q2 2022 Aug 01, 2022	BUY	$7.94 - $12.96 $1,349 - $2,203	170 New	170 $2,000
Q2 2021 Jul 27, 2021	SELL	$18.57 - $35.68 $9,285 - $17,840	-500 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$31.0 - $55.72 $15,500 - $27,860	500 New	500 $17,000
Q1 2020 Apr 22, 2020	SELL	$23.3 - $45.96 $11,650 - $22,980	-500 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$34.58 - $48.06 $17,290 - $24,030	500 New	500 $21,000
Q2 2019 Jul 24, 2019	SELL	$35.13 - $55.53 $17,565 - $27,765	-500 Closed	0 $0
Q1 2019 Apr 23, 2019	BUY	$42.83 - $59.91 $12,849 - $17,973	300 Added 150.0%	500 $27,000
Q4 2018 Feb 07, 2019	BUY	$37.97 - $60.16 $7,594 - $12,032	200 New	200 $9,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.